Nanalysis Scientific Corp. (NSCIF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nanalysis Scientific Corp. (NSCIF) trades at $0.09 with AI Score 50/100 (Grade B). Nanalysis Scientific Corp. develops and sells compact nuclear magnetic resonance (NMR) spectrometers and magnetic resonance imaging equipment. Market cap: $10.33M, Sector: Technology.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for NSCIF: NSCIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NSCIF against Technology peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
NSCIF: the 1 perspectives are evenly split.
How is this calculated? →Nanalysis Scientific Corp. (NSCIF) Technology Profile & Competitive Position
Nanalysis Scientific Corp. specializes in compact NMR spectrometers and MRI equipment, catering to diverse sectors like pharmaceuticals and chemicals. With a global distribution network and a focus on innovative analytical instruments, Nanalysis operates in a competitive technology landscape, balancing growth opportunities with financial challenges.
What Is the Investment Thesis for NSCIF?
Nanalysis Scientific Corp. presents a compelling investment case centered on its innovative compact NMR technology and diverse market applications. Key value drivers include expanding adoption of compact NMR in industries seeking cost-effective and accessible analytical solutions. The company's growth catalysts involve penetrating new markets, launching advanced software modules, and leveraging its global distribution network. While Nanalysis operates in a high-growth sector, potential risks include negative profit margins (-29.7%), competition from established players, and the need for continuous innovation to maintain its technological edge. Investors should closely monitor the company's ability to improve profitability, expand its customer base, and capitalize on growth opportunities in the analytical instruments market. The company's beta of 0.08 indicates low volatility compared to the overall market.
Based on FMP financials and quantitative analysis
NSCIF Key Highlights
- Market capitalization of $10.33M indicates a small-cap company with potential for growth.
- Negative P/E ratio of -1.29 reflects current losses, requiring focus on profitability improvements.
- Gross margin of 27.0% demonstrates the company's ability to generate revenue above the cost of goods sold.
- Profit margin of -29.7% highlights the need for cost management and revenue growth to achieve profitability.
- The company operates in the technology sector, specifically within the hardware, equipment, and parts industry, indicating exposure to innovation and technological advancements.
Who Are NSCIF's Competitors?
NSCIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BNSOF Bonso Electronics International Inc. | $2.12 | -11.30% | $10.30M | 45 |
| GUER Guerrilla RF, Inc. | $2.85 | -4.53% | $30.28M | 61 |
| PLCKF Plurilock Security Inc. | $0.09 | -2.47% | $7.39M | 35 |
| MDA Macdonald Dettwiler & Associate | $42.11 | +3.34% | 6B | 66 |
| WATT Energous Corporation | $19.29 | -19.93% | $28.65M | 65 |
| SELX Selecta Biosciences, Inc. | $0.34 | +580.00% | $12.78M | 64 |
| APH Amphenol Corporation | $166.89 | +1.40% | $205.31B | 63 |
| NEON Neonode Inc. | $0.99 | +6.61% | $16.58M | 52 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NSCIF's Key Strengths?
- Innovative compact NMR technology.
- Diverse customer base across multiple industries.
- Global distribution network.
- Integrated software solutions.
What Are NSCIF's Weaknesses?
- Negative profit margins.
- Small market capitalization.
- Dependence on continuous innovation.
- Limited brand recognition compared to larger competitors.
What Could Drive NSCIF Stock Higher?
- Launch of advanced software modules for NMR spectrometers, enhancing data analysis capabilities.
- Expansion of the global distribution network to penetrate new markets and increase sales.
- Continuous innovation in compact NMR technology to maintain competitive edge.
- Strategic partnerships and acquisitions to expand product portfolio and access new technologies.
What Are the Key Risks for NSCIF?
- Financial-distress signal — its Altman Z-Score of -1.07 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-44.8%) — the business is not currently generating profit on shareholder capital.
- Negative profit margins require significant improvement in cost management and revenue growth.
- Competition from established players with greater resources and brand recognition.
- Technological obsolescence could render existing products less competitive.
- Economic downturns could reduce customer spending on analytical instruments.
- Limited liquidity on the OTC market increases price volatility and trading risks.
What Are the Growth Opportunities for NSCIF?
- Expanding Market Penetration: Nanalysis has the opportunity to expand its market penetration by targeting new geographic regions and industries. The global analytical instruments market is projected to reach $75 billion by 2028, driven by increasing demand for advanced analytical solutions. By leveraging its global distribution network and tailoring its products to specific market needs, Nanalysis can increase its market share and revenue growth. Timeline: Ongoing.
- Product Innovation and Development: Continuous innovation in NMR technology is crucial for Nanalysis to maintain its competitive edge. The company can invest in developing advanced software modules, enhancing the capabilities of its compact NMR spectrometers, and exploring new applications for its technology. This will attract new customers and drive revenue growth. The company should focus on R&D to stay ahead of competitors. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Nanalysis can pursue strategic partnerships and acquisitions to expand its product portfolio, access new technologies, and enter new markets. Collaborating with complementary technology providers and acquiring companies with innovative analytical solutions can accelerate growth and enhance the company's competitive position. Timeline: Ongoing.
- Focus on Software Solutions: Nanalysis can capitalize on the increasing demand for software-driven analytical solutions by developing advanced software modules and integrating them with its NMR spectrometers. These software solutions can provide enhanced data analysis, automation, and user-friendly interfaces, attracting customers seeking comprehensive analytical solutions. The global market for analytical software is expected to grow significantly. Timeline: Ongoing.
- Leveraging the RS2D Segment: The RS2D segment, which manufactures cutting-edge electronics components, provides a unique growth opportunity for Nanalysis. By expanding the production and sales of these components to other analytical instrument manufacturers, Nanalysis can diversify its revenue streams and capitalize on the growing demand for precision electronics in the analytical instruments market. Timeline: Ongoing.
What Opportunities Does NSCIF Have?
- Expanding market penetration in emerging economies.
- Developing advanced software modules for NMR data analysis.
- Strategic partnerships and acquisitions.
- Increasing demand for portable analytical instruments.
What Threats Does NSCIF Face?
- Competition from established players with greater resources.
- Technological obsolescence.
- Economic downturns affecting customer spending.
- Regulatory changes impacting the analytical instruments market.
What Are NSCIF's Competitive Advantages?
- Proprietary compact NMR technology provides a unique selling proposition.
- Established global distribution network ensures broad market reach.
- Diverse customer base across various industries reduces dependence on a single sector.
- Integrated software solutions enhance the value of NMR spectrometers.
What Does NSCIF Do?
Nanalysis Scientific Corp., founded to revolutionize NMR technology, develops, manufactures, and sells compact NMR spectrometers and magnetic resonance imaging (MRI) equipment. These instruments cater to a wide array of industries, including pharmaceutical, biotech, chemical, security, food, materials, and education. The company operates through three key segments: Nanalysis, which focuses on the core NMR products; RS2D, specializing in cutting-edge electronics components for analytical instruments; and Corporate, handling overall management and strategy. Nanalysis offers software module packages and provides ongoing monitoring and support services for its NMR technologies. From its headquarters in Calgary, Canada, Nanalysis has expanded its reach through a direct sales force and a global network of distributors. The company's products are used in various applications, such as quality control, research and development, and material analysis. Nanalysis aims to provide accessible and user-friendly NMR solutions, differentiating itself from traditional, larger-scale NMR systems. The company's growth strategy involves continuous innovation in NMR technology, expanding its product portfolio, and penetrating new markets. Nanalysis faces competition from established players in the analytical instruments market, requiring ongoing investment in research and development to maintain its competitive edge.
What Products and Services Does NSCIF Offer?
- Develops and manufactures compact nuclear magnetic resonance (NMR) spectrometers.
- Creates magnetic resonance imaging (MRI) equipment.
- Offers solutions for pharmaceutical, biotech, chemical, and other industries.
- Provides software module packages for data analysis and automation.
- Manufactures electronics components for precision analytical instruments.
- Offers monitoring and support services for NMR technologies.
- Sells products directly and through a global distributor network.
How Does NSCIF Make Money?
- Sells compact NMR spectrometers and MRI equipment to various industries.
- Generates revenue from software module packages and support services.
- Manufactures and sells electronics components for analytical instruments.
- Distributes products through a direct sales force and a global network of distributors.
What Industry Does NSCIF Operate In?
Nanalysis Scientific Corp. operates in the analytical instruments market, a segment of the broader technology sector. The industry is characterized by continuous innovation, driven by advancements in technology and increasing demand for precise analytical solutions. Key trends include the adoption of compact and portable instruments, growing applications of NMR technology in various industries, and increasing demand for software-driven analytical solutions. Competitors include established players offering traditional NMR systems and other analytical instruments. Nanalysis aims to differentiate itself through its focus on compact NMR technology, user-friendly solutions, and a diverse range of applications.
Who Are NSCIF's Key Customers?
- Pharmaceutical companies using NMR for drug discovery and quality control.
- Biotech firms employing NMR for protein analysis and research.
- Chemical companies utilizing NMR for material analysis and reaction monitoring.
- Educational institutions using NMR for teaching and research purposes.
FY2026 estForward Outlook
Wall Street analysts project Nanalysis Scientific Corp. revenue of about $42.2M for fiscal 2026, with EPS near $-0.01.
NSCIF Valuation & Market Position
With a $10.33M market cap, Nanalysis Scientific Corp. sits in the micro-cap segment of the market. Relative to its peer group, NSCIF's quantitative score of 50/100 is roughly in line with the peer average of 54/100.
ROE -45%Key Financial Metrics
Return on equity for Nanalysis Scientific Corp. stands at -44.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -16.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.02 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -33.6%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
Nanalysis Scientific Corp.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.07 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Nanalysis Scientific Corp. operates in the Medical - Specialties industry within the Healthcare sector. It is headquartered in Calgary, CA. The company is led by CEO Sean Krakiwsky. NSCIF has traded publicly since 2020.
NSCIF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Nanalysis's future, indicating that executives believe in the company's potential growth.
- Community sentiment has shifted positively, with discussions highlighting innovative product developments that could enhance market position.
- The growing interest in quantum technologies aligns with Nanalysis's offerings, positioning them well in a rapidly expanding sector.
- Recent partnerships and collaborations have been perceived positively, enhancing the company's credibility and potential for future contracts.
Bear Case
- Concerns over market competition are rising, with analysts noting that larger companies might overshadow Nanalysis's market share.
- Community discussions reflect skepticism regarding the scalability of Nanalysis's business model, raising doubts about sustainable growth.
- Recent earnings reports have shown slower-than-expected revenue growth, leading to increased caution among investors.
- The overall market sentiment is mixed, with macroeconomic factors causing uncertainty in tech investments, affecting Nanalysis's stock perception.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NSCIF Latest News
-
Nanalysis Scientific Posts Narrower Loss, Higher Revenue for First Quarter
Yahoo! Finance: NSCIF News · May 20, 2026
-
Nanalysis Announces First Quarter 2026 Results
prnewswire.com · May 20, 2026
-
Nanalysis Announces First Quarter 2026 Conference Call
prnewswire.com · May 13, 2026
NSCIF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NSCIF.
Price Targets
Wall Street price target analysis for NSCIF.
NSCIF MoonshotScore
What does this score mean?
The MoonshotScore rates NSCIF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Hardware, Equipment & PartsLeadership: Sean Krakiwsky
CEO
Sean Krakiwsky serves as the CEO of Nanalysis Scientific Corp. His background includes extensive experience in managing and growing technology companies. He has a proven track record in strategic planning, product development, and market expansion. Prior to joining Nanalysis, Krakiwsky held leadership positions in various technology firms, where he focused on driving innovation and increasing shareholder value. His expertise spans across multiple areas, including sales, marketing, and operations.
Track Record: Under Sean Krakiwsky's leadership, Nanalysis Scientific Corp. has focused on expanding its global presence and enhancing its product offerings. Key milestones include the development of advanced software modules for NMR spectrometers and the establishment of strategic partnerships to penetrate new markets. Krakiwsky has also overseen efforts to improve operational efficiency and reduce costs. He manages 249 employees.
NSCIF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Nanalysis Scientific Corp. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide comprehensive financial disclosures. Investing in OTC Other stocks carries higher risks compared to stocks listed on major exchanges due to the lack of regulatory oversight and transparency. These stocks are often more speculative and may be subject to wider price fluctuations.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Low trading volume and liquidity can lead to price volatility.
- Higher risk of fraud or manipulation due to less regulatory oversight.
- Potential for delisting or trading suspension.
- Difficulty in obtaining accurate and timely information about the company.
- Verify the company's registration and legal standing.
- Obtain and review available financial statements.
- Assess the company's management team and their track record.
- Research the company's industry and competitive landscape.
- Evaluate the company's business model and revenue streams.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- The company develops and manufactures physical products (NMR spectrometers and MRI equipment).
- Nanalysis Scientific Corp. has a global distribution network, suggesting established operations.
- The company serves diverse industries, indicating a broad customer base.
- The company has been in operation for several years, suggesting some level of stability.
- The company has a CEO and management team in place, indicating organizational structure.
What Investors Ask About Nanalysis Scientific Corp. (NSCIF) — Technology
What does Nanalysis Scientific Corp. do?
Nanalysis Scientific Corp. specializes in developing, manufacturing, and selling compact nuclear magnetic resonance (NMR) spectrometers and magnetic resonance imaging (MRI) equipment. These instruments are used across diverse industries, including pharmaceuticals, biotech, chemicals, and education, for applications such as quality control, research and development, and material analysis. The company operates through three segments: Nanalysis, RS2D, and Corporate, offering a range of products, software solutions, and support services. Nanalysis aims to provide accessible and user-friendly NMR solutions, differentiating itself from traditional, larger-scale NMR systems.
What are the main risks for NSCIF?
Nanalysis Scientific Corp. faces several key risks, including negative profit margins, competition from established players, and technological obsolescence. The company's negative profit margins highlight the need for improved cost management and revenue growth. Competition from larger companies with greater resources and brand recognition poses a significant challenge. The risk of technological obsolescence requires continuous investment in research and development to maintain a competitive edge. Additionally, economic downturns could reduce customer spending on analytical instruments, impacting the company's sales and revenue. The company's OTC listing also introduces liquidity risks.
What are the key factors to evaluate for NSCIF?
Nanalysis Scientific Corp. (NSCIF) holds an AI score of 50/100 (moderate). Not financial advice.
How frequently does NSCIF data refresh on this page?
NSCIF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NSCIF's recent stock price performance?
Nanalysis Scientific Corp. (NSCIF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative compact NMR technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NSCIF overvalued or undervalued right now?
Valuing Nanalysis Scientific Corp. (NSCIF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying NSCIF?
Before investing in Nanalysis Scientific Corp. (NSCIF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding NSCIF to a portfolio?
Key strength of Nanalysis Scientific Corp. (NSCIF): Innovative compact NMR technology. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending, limiting the availability of analyst consensus and detailed financial analysis.
- OTC market listing introduces higher risks and limited information compared to major exchanges.
- Financial data is based on available information and may not be comprehensive.